Skip to main content

Day: March 18, 2026

OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights

MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (the “OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), today announced a strategic collaboration with Navidence to help research organizations transform rapidly expanding healthcare data into clear, actionable real-world evidence. What This Collaboration Means for the Pharma Market Pharmaceutical companies face growing pressure to integrate high-quality RWD for regulatory submissions, post-market surveillance, and AI model training. Navidence’s platform enables precise definition of health data needs via Computable Operational Definitions (CODefs)—standardized, executable queries that translate complex study criteria (e.g., patient cohorts by diagnosis, treatment, or...

Continue reading

Saltchuk Resources, Inc. and Great Lakes Dredge & Dock Corporation Announce Tender Offer for Any and All 5.25% Senior Notes due 2029 of Great Lakes Dredge & Dock Corporation and Related Consent Solicitation

Tender Offer Made in Connection with Parties’ Pending Business Combination Expected to Close Early in the Second Quarter HOUSTON and SEATTLE, March 18, 2026 (GLOBE NEWSWIRE) — Saltchuk Resources, Inc. (the “Offeror”) and Great Lakes Dredge & Dock Corporation (NASDAQ:GLDD) (the “Company”) announced that the Offeror has commenced a cash tender offer (the “Tender Offer”) for any and all of the Company’s 5.25% Senior Notes due 2029 (the “Notes”). In conjunction with the Tender Offer, the Offeror is soliciting (the “Consent Solicitation”) consents (each, a “Consent” and, collectively, the “Consents”) from holders of the Notes (each, a “Holder” and, collectively, the “Holders”) to amend certain provisions (the “Proposed Amendments”) of the indenture, dated as of May 25, 2021 (as supplemented from time to time prior to the date hereof,...

Continue reading

MACOM’s Microwave and Optical Comprehensive Solutions on Display at SATShow Week 2026

LOWELL, Mass., March 18, 2026 (GLOBE NEWSWIRE) — MACOM Technology Solutions Inc. (“MACOM”), a leading supplier of semiconductor products, will showcase its latest RF and optoelectronics solutions for satellite communications (SATCOM) at Booth 1637, during SATShow Week, taking place March 24 to 26, 2026 in Washington, D.C. These solutions can enable higher frequency bands, improved power efficiency and more scalable architectures, which are critical to next-generation satellite networks. MACOM will host live demonstrations highlighting advanced semiconductor and optical technologies designed to support the evolving SATCOM needs, including direct-to-device, high frequency RF and optical connectivity solutions. With more than seven decades of experience serving the space industry, MACOM continues to expand its product portfolio and...

Continue reading

LiveOne (Nasdaq: LVO) Raises 2026 Cost Savings Target from $5M to $7.5M ($3.5M Completed); Increases Payables Conversion Target from $11M to $13M+ at $7.50 per share ($5M Completed)

Deploys AI (Anthropic Claude, OpenAI) to Slash Costs, Reduce Workforce from 350 to 78 (~19% Reduction this Quarter), Drive All Subsidiaries to Positive Adjusted EBITDA*Additional ~$1.5M CPS savings expected by year-end Launching two new Fortune 500 B2B partnerships reaching 100M+ monthly subscribers ~$5.7M remaining under share repurchase plan Acquired 900k+ shares of PodcastOne (Nasdaq: PODC)LOS ANGELES, March 18, 2026 (GLOBE NEWSWIRE) — LiveOne, Inc. (Nasdaq: LVO), a creator-first, music, entertainment and technology platform, today announced that it has increased its projected 2026 cost savings target to more than $7.5 million, driven by continued operational efficiencies and workforce optimization initiatives. The Company also expanded its payables conversion initiative to more than $13 million at $7.50 per share, further...

Continue reading

Orbit International Corp. Reports 2025 Year End Results

2025 Net Loss of $5,025,000 ($1.51 loss per share) vs. Net Loss of $646,000 ($0.19 loss per share) in 2024 2025 EBITDA, As Adjusted, was a loss of $3,971,000 ($1.19 loss per share) vs. earnings of $159,000 ($0.05 per diluted share) in 2024 Fourth Quarter 2025 Net Loss of $708,000 ($0.21 loss per share) vs. Net Loss of $252,000 ($0.08 loss per share) in Prior Year Period Fourth Quarter 2025 EBITDA, As Adjusted, was a loss of $465,000 ($0.14 loss per share) vs. earnings of $383,000 ($0.11 per diluted share) in Prior Year Period Backlog at December 31, 2025 was approximately $12.2 million compared to approximately $12.0 million at December 31, 2024 HAUPPAUGE, N.Y., March 18, 2026 (GLOBE NEWSWIRE) — Orbit International Corp. (OTCID Basic Market:ORBT) today announced results for the fourth quarter and the year ended December 31, 2025. Fourth...

Continue reading

env zero and CloudQuery Announce Merger to Create the Industry’s First Unified Cloud Intelligence Platform

The combined entity will provide a unified solution for cloud governance and asset management, enabling enterprise platform teams to ensure resiliency across the entire cloud lifecycle BOSTON, March 18, 2026 (GLOBE NEWSWIRE) — env zero (envzero.com), the leader in Infrastructure as Code (IaC) management and governance, and CloudQuery (cloudquery.io), the leading cloud asset management platform, today announced the successful close of their merger. The combined company will operate under the env zero brand, creating a powerhouse in the cloud operations space. The merger addresses a critical gap in the market: Modern cloud teams struggle with infrastructure that exists outside Infrastructure as Code. Automation platforms can’t see it, and discovery tools can’t safely fix it. By combining CloudQuery’s complete cloud asset inventory...

Continue reading

Banzai to Host Fourth Quarter and Fiscal Year 2025 Financial Results Conference Call on Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time

SEATTLE, March 18, 2026 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading AI-powered sales & marketing technology company, will hold a conference call on Tuesday, March 31, 2026, at 4:30 p.m. Eastern Time to discuss its financial results for the fourth quarter ended December 31, 2025, as well as review ongoing initiatives and anticipated milestones. Banzai Founder & CEO Joe Davy and CFO Dean Ditto will host the conference call, followed by a question-and-answer session. The conference call will be accompanied by a presentation, which can be viewed during the webcast or accessed via the investor relations section of the Company’s website here. To access the call, please use the following information:Date: Tuesday, March 31, 2026Time: 4:30 p.m. Eastern Time (1:30 p.m....

Continue reading

GSI Technology Concludes Strategic Alternatives Review

SUNNYVALE, Calif., March 18, 2026 (GLOBE NEWSWIRE) — GSI Technology, Inc. (Nasdaq: GSIT) today announced that its Board of Directors has concluded the Company’s previously announced review of strategic alternatives. In reaching this determination, the Board considered the Company’s operational and financial progress and the strengthened balance sheet following the October 2025 capital raise, which provided additional resources to support GSI Technology’s go-forward plan. As part of the review, the Board and its advisors engaged with multiple parties and evaluated a range of potential alternatives. After careful consideration, the Board concluded that continuing to execute the Company’s standalone strategy is in the best interests of stockholders at this time. The Company intends to focus on driving commercialization of its high-performance...

Continue reading

Siemens Healthineers Launches Brain Health Research Portfolio with First Biomarker Assays Now Available

Brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays now available for research useBrain ImageSiemens Healthineers announced today its offerings for brain health research are expanding, with the brain-derived, fully automated Atellica IM Phosphorylated tau 217 (pTau217) and Atellica IM Brain Derived Tau (BDTau) assays now available for research use.Tarrytown, New York, USA, March 18, 2026 (GLOBE NEWSWIRE) —Research assays help generate evidence about whether biomarkers can advance disease management Novel RUO tests can help scientists understand neurological function and disease progression Collaborative research is underway to translate scientific discovery into actionable evidenceSiemens Healthineers announced today its offerings for brain health...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.